COMMUNIQUÉS West-GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results
09/11/2018
-- Presented Updated Data from Phase 2 Basket Studies in Bardet-Biedl Syndrome (BBS) and Alström Syndrome at the 57 th Annual European Society for Pediatric Endocrinology (ESPE) Meeting -- -- Launched TEMPO Registry for [...]
Spring Bank Announces Additional Inarigivir Results at AASLD Conference
09/11/2018
*Results from full 24 weeks of dosing from the first three cohorts of the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted *New data from ACHIEVE trial demonstrates that increased baseline serum IP-10, a [...]
Scholar Rock Demonstrates that Highly Specific TGFβ1 Inhibition Combined with Anti-PD1 Drives Tumor Regression and Survival Benefit in Preclinical Models of Primary Resistance to Checkpoint Blockade Therapy
09/11/2018
Preclinical Data Presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting Shows Highly Specific Inhibitor of TGFβ1, SRTβ1-Ab3, Renders Resistant Solid Tumors Vulnerable to PD1 Blockade Isoform- [...]
Solid Biosciences to Present at the Credit Suisse Healthcare Conference
09/11/2018
CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27 th Annual Healthcare Conference on Wednesday, November 14, [...]
Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas
09/11/2018
Data presented at Society for Immunotherapy of Cancer's (SITC) 33 rd Annual Meeting demonstrate ADU-S100 (MIW815) is well-tolerated with no dose-limiting toxicities reported Preliminary signs of clinical and biomarker [...]
Tonix Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights
09/11/2018
New Phase 3 Trial of Tonmya® for the Treatment of PTSD to Commence First Quarter 2019 NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix or the Company), a clinical- [...]
Fortress Biotech Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
09/11/2018
NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology [...]
Wave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update
09/11/2018
CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases [...]
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2018 Financial Results
09/11/2018
Investor Conference Call to be Held Today, Friday, November 9, 2018 at 8:30 AM ET NEW YORK, Nov. 09, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third [...]
Oxford Immunotec Reports Third Quarter 2018 Financial Results
09/11/2018
Closed transformative deal to sell U.S. laboratory services business to Quest Diagnostics T-SPOT ® .TB tests sold in the third quarter exceeded one million tests for the first time Significant improvement in GAAP net [...]
Oncolytics Biotech® Announces Presentation at the Society for Immunotherapy of Cancer 2018 Annual Meeting Showcasing Upregulation of PD-L1 Expression with Reovirus Infection
09/11/2018
- Oncolytic virus enhances immune checkpoint inhibitor response in prostate cancers - CALGARY, Alberta and SAN DIEGO, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently [...]
Neos Therapeutics Reports Third Quarter 2018 Financial Results
09/11/2018
Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical company focused on developing [...]
CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology
09/11/2018
--CRISPR Therapeutics Gains Additional Rights to MaxCyte’s Cell Engineering Technology to Develop CRISPR/Cas9-Based Cell Therapies in Immuno-Oncology-- ZUG, Switzerland and CAMBRIDGE, Mass. and GAITHERSBURG, Md., Nov. [...]
VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update
09/11/2018
-- Completion of vaccination and enrollment in Sci-B-Vac® PROTECT and CONSTANT Phase 3 studies, respectively -- -- Encouraging early immunologic data observed in Phase 1/2a study of VBI-1901 for the treatment of [...]
Antares Pharma Announces Data Presentation at the 2018 Sexual Medicine Society Scientific Annual Meeting
09/11/2018
XYOSTED™ AMBULATORY BLOOD PRESURE ABSTRACT HAS BEEN SELECTED FOR POSTER PRESENTATION EWING, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from the 26-week Phase 3 [...]
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
09/11/2018
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3 interim analysis [...]
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2018 and Recent Progress
09/11/2018
LOS ANGELES, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the gut microbiome to treat [...]
PLx Pharma Inc. Reports Third Quarter 2018 Results
09/11/2018
PLx has identified the alternate supply of a key ingredient for Vazalore HOUSTON, Nov. 09, 2018 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company [...]
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference 2018
09/11/2018
RANCHO CUCAMONGA, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell, President, and Bill Peters, CFO will be presenting at the Jefferies London [...]

Pages